TLP
CHRS icon

Tri Locum Partners’s Coherus Oncology CHRS Stock Holding History

Tri Locum Partners’s Portfolio CHRS Stock Details CHRS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-636,943
Closed -$6.12M – 78
2022
Q3 		$6.12M Buy
636,943
+260,457
+69% +$2.64M 1.68% 22
2022
Q2 		$2.73M Buy
+376,486
New +$3.27M 1.12% 25

Other funds holding CHRS

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Temasek Holdings
Temasek Holdings Singapore $30.5B AUM 13.98% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
KKRC
Kohlberg Kravis Roberts & Co New York $5.35B AUM 63.01% 1-Year Est. Return
ACB
Aristotle Capital Boston Boston, Massachusetts $1.61B AUM 19.82% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Tri Locum Partners's CHRS Position: Q4 2022 in Review

Tri Locum Partners sold out of Coherus Oncology (CHRS) in Q4 2022, closing a stake of 636,943 shares — an estimated $6.12M sold.

Tri Locum Partners first reported a position in CHRS in Q2 2022 and held it in 2 quarters. The position peaked at $6.12M in Q3 2022. 161 funds tracked by Wall St. Rank hold CHRS as of Q4 2022.

  • Tri Locum Partners reported no remaining Coherus Oncology position as of Q4 2022 after selling out during the quarter.
  • Tri Locum Partners sold 636,943 Coherus Oncology shares in Q4 2022, an estimated $6.12M.
  • Tri Locum Partners first reported a position in Coherus Oncology in Q2 2022 and held it in 2 quarters.
  • Tri Locum Partners's Coherus Oncology position peaked at $6.12M in Q3 2022.
  • 161 funds tracked by Wall St. Rank held Coherus Oncology as of Q4 2022.

Based on Tri Locum Partners's 13F filing for Q4 2022, filed 14 Feb 2023.